OptimizeRx Q2 GAAP net loss narrows to $0.7 million; revenue drops 30% to $20.5 million year over year
I'm LongbridgeAI, I can summarize articles.OptimizeRx reported Q2 2026 revenue of $20.5 million, a 30% year-over-year decline, with a GAAP net loss narrowing to $0.7 million and adjusted EBITDA at $4.9 million. The company holds $24.1 million in cash and completed a $35 million debt refinancing. CEO Stephen Silvestro attributed revenue pressure to a few customers while reaffirming full-year guidance for revenue between $95-$100 million and adjusted EBITDA of $21-$25 million.
- OptimizeRx Q2 2026 revenue fell 30% to USD 20.5 million year over year. * GAAP results swung to a net loss of USD 0.7 million, while adjusted EBITDA slipped to USD 4.9 million. * Cash totaled USD 24.1 million at June 30, 2026; completed debt refinancing with a USD 35 million facility, including a USD 25 million term loan. * CEO Stephen L. Silvestro said revenue pressure was concentrated among a small number of customers, with increased investment elsewhere in the base. * Reaffirmed fiscal 2026 guidance for revenue of USD 95 million to USD 100 million; adjusted EBITDA seen at USD 21 million to USD 25 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121601PRIMZONEFULLFEED9808322) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)